This can occur in patients following CD19 CAR and can be recapitulated in a syngeneic murine model in which pre B cell ALL is driven by the clinically relevant E2a:PBX1 transgene allowing comprehensive study. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.